<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01935830</url>
  </required_header>
  <id_info>
    <org_study_id>201307040</org_study_id>
    <nct_id>NCT01935830</nct_id>
  </id_info>
  <brief_title>LAAM-HAART PET Imaging</brief_title>
  <official_title>Efavirenz and Ritonavir Influence on Human Brain Levo-acetylmethadol (LAAM) Disposition Assessed Using PET Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of the antiretroviral drugs efavirenz
      and ritonavir on human brain LAAM disposition in vivo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cerebral [11C]LAAM distribution volume</measure>
    <time_frame>approximately 3 months</time_frame>
    <description>Blood tests, MRI and PET data analysis and interpretation</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>LAAM arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[11C]LAAM 15-20 mCi (maximum administered mass of 10 ug)
Efavirenz, oral capsules, 600 mg
Ritonavir, oral capsules, 100 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>[11c] LAAM</intervention_name>
    <description>intravenous administration of 15-20 mCi of [11c] LAAM.</description>
    <arm_group_label>LAAM arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>Pretreatment with oral ritonavir for 3 days followed by intravenous administration of 15-20 mCI of [11c] LAAM.</description>
    <arm_group_label>LAAM arm</arm_group_label>
    <other_name>Kaletra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <description>Pretreatment with oral Efavirenz 600 mg orally every night x 14 days followed by intravenous administration of 15-20 mCI of [11c] LAAM.</description>
    <arm_group_label>LAAM arm</arm_group_label>
    <other_name>Sustiva, Atripla</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion

        Each subject must meet all of the following criteria:

          1. Male or non-pregnant female volunteer, 18-50 yr old

          2. Good general health with no known major medical conditions

          3. BMI &lt; 33

          4. Provide informed consent

        Exclusion Criteria

        Subjects will not be enrolled if any of the following criteria exist:

          1. Known history of liver or kidney disease

          2. History of major medical conditions

          3. HIV seropositive

          4. Fasting blood glucose &gt; 110 mg/dl (because HAART can cause glucose intolerance)

          5. Family history of type 2 diabetes

          6. Use of prescription or non prescription medications, herbals or foods known to be
             metabolized by or altering P-glycoprotein or CYP3A (hormonal birth control medications
             are acceptable if alternative means of contraception are used)

          7. Females who are pregnant or nursing

          8. Females taking hormonal contraceptives who are unwilling to use alternative means of
             contraception

          9. Contraindications to MRI (e.g., metal implants or splinters in the body; a worn or
             implanted medical device, such as a pacemaker or drug pump; inability to lie flat for
             up to one hour; claustrophobia) or contraindications to PET scanning (e.g., inability
             to lie flat for up to one hour, claustrophobia, current

         10. Current or recent (within 12 months prior to screening) participation in research
             studies involving radiation exposure such that the total research-related radiation
             dose to the subject in any given year would exceed the limits set forth in the US Code
             of Federal Regulations (CFR) Title 21 Section 361.1
             (http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?FR=361.1))
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evan D Kharasch, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2013</study_first_submitted>
  <study_first_submitted_qc>August 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2013</study_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PET Imaging</keyword>
  <keyword>Efavirenz</keyword>
  <keyword>Ritonavior [11C] LAAM</keyword>
  <keyword>Healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Methadyl Acetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

